Real-world use of GLP-1 drugs show lower weight loss in new a new study; new AMA policy to reduce breast cancer risk; a guideline on lifestyle intervention for diabetes care – Morning Medical Update

Real-world use of obesity drugs shows lower weight loss due to dropouts, low doses

A Cleveland Clinic study found that patients using injectable GLP-1 medications semaglutide and tirzepatide for obesity lost significantly less weight in clinical settings than in trials, largely due to early discontinuation and low maintenance dosing. Published in Obesity, the study also found poorer blood sugar control in patients with prediabetes who stopped treatment early, underscoring the need for adherence and optimal dosing to maximize benefits.

New AMA policy to reduce breast cancer risk

The American Medical Association (AMA) has adopted a new policy encouraging physicians to educate patients about lifestyle strategies — including plant-based diets, physical activity, weight management and limited alcohol consumption — to lower breast cancer risk. Prompted by low public awareness of prevention measures, the move highlights growing support for proactive, evidence-based cancer prevention efforts.

New guideline on lifestyle interventions for diabetes care

A first-of-its-kind clinical guideline from the American College of Lifestyle Medicine (ACLM) outlines practical, evidence-based strategies for using lifestyle changes to treat or even remit type 2 diabetes and prediabetes. Published in the American Journal of Lifestyle Medicine, the guideline emphasizes personalized nutrition, physical activity, sleep, stress management and medication de-prescribing frameworks. It aims to fill a critical gap in existing diabetes care by offering specific tools for clinicians and patients to implement sustainable behavior change.